A new model accurately predicts 3-year mortality for patients with resected esophageal or gastroesophageal junction cancer, aiming to enhance surgical decision-making.

• Internally validated with 2,124 Ontario patients, it shows an AUC of 0.77, indicating good predictive power.
• Externally validated with 318 Manitoba patients, it maintains strong results, AUC of 0.73.

This tool may improve patient selection and treatment personalization, leading to better outcomes.

• A web-based interface is being developed for real-world clinical use, enhancing shared decision-making.